Pre-Transplant Essential Data

**COMORBID CONDITIONS**

120. **Is there a history of mechanical ventilation?**
   - [ ] Yes
   - [ ] No

121. **Is there a history of severe arrhythmia?**
   - [ ] Yes
   - [ ] No

122. **Were there clinically significant co-existing disease or organ impairment at time of patient assessment prior to preparative regimen?**
   - [ ] Yes
   - [ ] No

   - **Yes**
     - **Noted**
     - **Comorbidity Definitions**

   26. **Arrhythmia**
   - Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias

   27. **Cardiac**
   - Coronary artery disease ≤ 50%

   28. **Cerebrovascular disease**
   - Transient ischemic attack or cerebrovascular accident

   29. **Diabetes**
   - Requiring treatment with insulin or oral hypoglycemics but not diet alone

   30. **Heart valve disease**
   - Except mitral valve prolapse

   31. **Hepatic, mild**
   - Chronic hepatitis, bilirubin > 1.5 × ULN, or AST/ALT > 2.5 × ULN

   32. **Hepatic, moderate/severe**
   - Liver cirrhosis, bilirubin > 1.5 × ULN, or AST/ALT > 2.5 × ULN

   33. **Infection**
   - Requiring continuation of antimicrobial treatment after day 0

   34. **Inflammatory bowel disease**
   - Crohn's disease or ulcerative colitis

   35. **Obesity**
   - Patients with a body mass index > 35 kg/m²

   36. **Peptic ulcer**
   - Requiring treatment

   37. **Psychiatric disturbance**
   - Depression or anxiety requiring psychiatric consult or treatment

   38. **Pulmonary, moderate**
   - DLco and/or FEV₁ ≤ 80% on slight activity

   39. **Pulmonary, severe**
   - DLco and/or FEV₁ ≤ 65% or dyspnea at rest or requiring oxygen

   40. **Renal, moderate/severe**
   - Serum creatineine > 2 mg/dL or >177 μmol/L, on dialysis, or prior renal transplantation

   41. **Rheumatologic**
   - SLE, RA, polymysitis, mixed CTD, or polymyalgia rheumatica

   42. **Solid tumor, prior**
   - Treated at any time point in the patient's past history, excluding nonmelanoma skin cancer

   43. **Other**
   - Treatment plan

   - **Yes**
   - **No**
   - **Noted**
   - **Comorbidity Definitions**

   - **44.**
   - **Specify:**

---

**Box A**

**GVHD PROPHYLAXIS (ALLO ONLY)**

145. Was GVHD prophylaxis planned/given?  
   - [ ] Yes
   - [ ] No

146. (Check all that apply)
   - [ ] ALG, ALS, ATG, ATS (after d0)
   - [ ] Corticosteroids
   - [ ] Cyclosporine (CSA)
   - [ ] ECP (extra-corporeal photopheresis)
   - [ ] FK 506 (Tacrolimus, Prograf)
   - [ ] Methotrexate (MTX)
   - [ ] In vivo monoclonal antibody (MAb)
   - [ ] Anti CD25 (Zenapax, Daclizumab, AntiTAC)
   - [ ] Campath
   - [ ] Etanercept (Enbrel)
   - [ ] Inflimixam (Remicade)
   - [ ] Other, specify

150. Mycophenolate (MMF, Cellcept)
160. Sirolimus (Rapamycin, Rapamune)
161. Other drug, specify

---

**Box B**

**POST-HSCT DISEASE THERAPY PLANNED AS OF DAY 0**

165. Is this HSCT part of a planned multiple (sequential) graft/HSCT protocol?  
   - [ ] Yes
   - [ ] No

166. Is additional post-HSCT therapy planned?  
   - [ ] Yes
   - [ ] No

167. (Check all that apply) Optional for non-U.S. centers
   - [ ] bortezomib (Velcade)
   - [ ] Cellular therapy (e.g. DCI, DLI)
   - [ ] Intrathelial Chemotherapy
   - [ ] Methotrexate (MTX)
   - [ ] Local radiotherapy
   - [ ] Rituximab (Rituxan, Mabthera)
   - [ ] Thalidomide (Thalomid)
   - [ ] Other, specify

170. OTHER TOXICITY MODIFYING REGIMEN

175. Was KGF (palifermin, Kepivance) started or is there a plan to use it?  
   - [ ] Yes
   - [ ] No
   - [ ] Masked trial

176. Was FGF (velarmin) started or is there a plan to use it?  
   - [ ] Yes
   - [ ] No
   - [ ] Masked trial

---

**Abbreviations**

- YYYYY = 4 digit year
- MM = 2 digit month
- DS = 2 digit day
- AHOP = Adult, Hematology, Oncology or Pediatric Unit
- ALLO = Allogeneic
- ANC = Absolute Neutrophil Count
- AUTO = Autologous
- BM = Bone Marrow
- BMT/CTN = Blood & Marrow Transplant Clinical Trials Network
- CIBMTR = Center for International Blood & Marrow Transplant Research
- CIC = Center Identification Code
- CMN = Cytomegalovirus
- CR = Complete Remission
- D = Disorders
- DCI = Donor Cell Infusion
- DF = Differential or function
- DLI = Donor Lymphocyte Infusion
- DOB = Date of Birth
- EBMT = European Group for Blood & Marrow Transplantation
- EBV = Epstein Barr Virus
- FACT = Foundation for the Accreditation of Cellular Therapy
- FGF = Fibroblast Growth Factor
- FISH = Fluorescent In-situ Hybridization
- Graft = Graft versus Host Disease
- HCT = Hematopoietic Stem Cell Transplant
- IA = Inherited Abnormalities
- IDOM = Inherited Disorders of Metabolism
- IFN = Interferon
- KGF = Keratinocyte Growth Factor
- KIT = Kit Ligand
- LCI = Lineage Criteria
- MDS = Myelodysplastic
- NMDP = National Marrow Donor Program
- NO = Not Otherwise Specified
- NOS = Not Otherwise Specified
- NTC = Not Typically Considered
- NTM = Not Typically Monitored
- NTI = Not Typically Interpreted
- NC = Not Completed
- NM = Not Measured
- NR = Not Recorded
- NS = Not Specified
- NTD = Not Typically Defined
- NTU = Not Typically Updated
- NTR = Not Typically Recommended
- NTX = Not Typically eXamined
- OT = Other Treatment
- POST-HSCT therapy planned
- SAA = Severe Aplastic Anemia
- SCTOD = Stem Cell Therapeutic Outcomes Database
- TBI = Total Body Irradiation
- TLD = Total Lymphoid Dose
- TLH = Total Lymphoid Haplotherapy
- TLI = Total Lymphoid Irradiation
- UCB = Umbilical Cord Blood
- Unit = Adult, Hematology, Oncology, Pediatric (AHOP)
- VOD = Veno-occlusive disease

**Source:** Blood, 2005 Oct 15;106(8):2912-2919
### Pre-Transplant Essential Data

#### Disease Classification Sheet

**ACUTE LEUKEMIAS**

Select most specific W.H.O. classification:

- [ ] Acute Myelogenous Leukemia (AML) (10)
- [ ] Acute Lymphoblastic Leukemia (ALL) (20)
- [ ] Acute Leukemias of ambiguous lineage (80)
- [ ] AML with recurrent genetic abnormalities
  - [ ] AML with t(8;21)(q22;q22), (AML1/ETO) (281)
  - [ ] AML with t(15;17)(q22;q12), (PML/RARα) and variants (M3) (283)
  - [ ] AML with 11q23 (MLL) abnormalities (284)
  - [ ] AML with multilineage dysplasia (285)
- [ ] AML, not otherwise categorized/(NOS)
  - [ ] AML, minimally differentiated/(M0) (286)
  - [ ] AML without maturation/(M1) (287)
  - [ ] AML with maturation/(M2) (288)
  - [ ] Acute Myelomonocytic Leukemia/(M4) (289)
  - [ ] Acute Monoblastic/Acute Monocytic Leukemia/(M5) (290)
  - [ ] Acute Erythroid Leukemia (erythroid/myeloid and pure erythroleukemia)/(M6) (291)
  - [ ] Acute Megakaryoblastic Leukemia/(M7) (292)
  - [ ] Acute Basophilic Leukemia (293)
  - [ ] Acute Panmyelosis with Myelofibrosis (294)
  - [ ] Myeloid Sarcoma (295)
  - [ ] AML, NOS (280)

177. Did AML transform from MDS or MPS? [ ] Yes [ ] No

178. Was AML therapy related? [ ] Yes [ ] No [ ] Unknown

179. Status at Transplantation:
- [ ] Never treated
- [ ] Complete Remission Failure (PIF)
- [ ] Complete Remission (CR) [ ] 1st [ ] 2nd [ ] 3rd or higher
- [ ] Relapse [ ] 1st [ ] 2nd [ ] 3rd or higher

180. Was imatinib mesylate given for pretransplant therapy anytime prior to start of prep regimen? [ ] Yes [ ] No [ ] Unknown

Complete entire MDS Section on Disease Classification page 4 and entire AML Section.

AML therapy related (check all that apply)
- [ ] Alkylating agent/radiation-related
- [ ] Topoisomerase II inhibitor-related
- [ ] Unknown
**Pre-Transplant Essential Data**

### Disease Classification Sheet

#### 177. CHRONIC MYELOGENOUS LEUKEMIA (CML)

- Philadelphia chromosome+, Ph+, t(9;22)(q34;q11), or variant OR bcr/abl+

#### 206. Did recipient receive treatment prior to this HSCT?

(Select all that apply)

- Yes
- No

**Mandatory for CIBMTR comprehensive Report Form Teams:**

- Combination chemotherapy
- Dasatinib (Sprycel)
- Hydroxyurea (HU)
- Imatinib mesylate (Gleevec, Glivec)
- Interferon

**Status at Transplantation:**

**Phase**

- Hematologic CR
- Chronic phase
- Accelerated phase
- Blast phase

**215.** (Check all that apply) [ ] 1st [ ] 2nd [ ] 3rd or higher

**216.** CML disease status before treatment that achieved this CR:

- Chronic phase
- Accelerated phase
- Blast phase

---

### Disease Classification

#### 177. MYELODYSPLASTIC OR MYELOPROLIFERATIVE DISEASES

- WHO: Myelodysplastic Syndromes (MDS)
- WHO: Chronic Myeloproliferative Diseases (MPS)

**Classification:**

- At diagnosis
  - RA (61)
  - RARS (65)
  - RAEB-1 (61)
  - RAEB-2 (62)
  - RCMD (64)
  - RCMD/RS (65)
  - Isolated 5q-syndrome (66)
  - MDS Unclassifiable (NOS) (50)

- At transplantation
  - AML

**If transformed to AML, indicate AML as primary disease; also complete Disease Classification page 3**

- MDS Unclassifiable (NOS) (50)

**224.** Date of MDS Dx:

**225.** Was Janus kinase 2 (jak2) gene mutation positive?

- Yes
- No
- Not Done

---

**226.** MDS/MPN/CMML

**227.** Status at Transplantation:

- Supportive care or treatment without chemotherapy
- Treated with chemotherapy
- Relapse after CR

**230.** MDS/MPN/CMML

**231.** CR

**232.** Number:

- 1st
- 2nd
- 3rd or higher

---

**233.** Other, specify:

---

**217.** CHRONIC MYELOGENOUS LEUKEMIA (CML) (40)

**205.** Ph+ (41)

**206.** Did recipient receive treatment prior to this HSCT? [ ] Yes [ ] No

**207.** Combination chemotherapy

**208.** Dasatinib (Sprycel)

**209.** Hydroxyurea (HU)

**210.** Imatinib mesylate (Gleevec, Glivec)

**211.** Interferon

**212.** nilotinib (Tasigna)

**213.** nilotinib (Tasigna)

**214.** nilotinib (Tasigna)

**215.** Number

<table>
<thead>
<tr>
<th>Number</th>
<th>For Chronic Phase and CR Only:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>1st</td>
</tr>
<tr>
<td>2nd</td>
<td>2nd</td>
</tr>
<tr>
<td>3rd or higher</td>
<td>3rd or higher</td>
</tr>
</tbody>
</table>

**216.** CML disease status before treatment that achieved this CR:

- Chronic phase
- Accelerated phase
- Blast phase

**217.** Cyto genetic remission:

- Complete
- No

**218.** Molecular remission (bcr/abl):

- Yes
- No
- bcr/abl unknown

---

**220.** Other, specify:

---

**221.** Number

<table>
<thead>
<tr>
<th>Number</th>
<th>For Chronic Phase and CR Only:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>1st</td>
</tr>
<tr>
<td>2nd</td>
<td>2nd</td>
</tr>
<tr>
<td>3rd or higher</td>
<td>3rd or higher</td>
</tr>
</tbody>
</table>

**222.** Cytogenetic remission:

- Cytogenetics unknown

**223.** Molecular remission (bcr/abl):

- Yes
- No
- bcr/abl unknown

---

**224.** Date of MDS Dx:

**225.** Was Janus kinase 2 (jak2) gene mutation positive?

- Yes
- No
- Not Done

---

**226.** MDS/MPN/CMML

**227.** Status at Transplantation:

- Supportive care or treatment without chemotherapy
- Treated with chemotherapy
- Relapse after CR

**228.** Number:

- 1st
- 2nd
- 3rd or higher

---

**229.** Other, specify:

---

**230.** MDS/MPN/CMML

**231.** CR

**232.** Number:

- 1st
- 2nd
- 3rd or higher

---

**233.** Other, specify:

---
## Pre-Transplant Essential Data

### Disease Classification Sheet

#### OTHER LEUKEMIAS (30)

- Atypical chronic myeloid leukemia (CML, NOS) 235.
- Ph-bcr/abl- (45)
- Ph-bcr unknown (46)
- Ph unknown/bcr- (48)
- Ph unknown/bcr unknown (49)
- Chronic Lymphocytic Leukemia (CLL), B-cell (71)
- Chronic Lymphocytic Leukemia (CLL), NOS (37)
- Prolymphocytic Leukemia (PLL), NOS (122)
- PLL, B-cell (73)
- PLL, T-cell (74)
- Other leukemia (39), specify: ______________________

#### LYMPHOMAS

### Hodgkin Lymphoma (150)

- Nodular lymphocyte predominant Hodgkin lymphoma (155)
- Lymphocyte-rich (151)
- Nodular sclerosis (152)
- Mixed cellularity (153)
- Lymphoma depleted (154)
- Hodgkin lymphoma, NOS (150)

#### Non-Hodgkin’s Lymphoma

- B-cell Neoplasms 244.
- Burkitt’s lymphoma/Burkitt cell leukemia (ALL L3) (111)
- High-grade B-cell lymphoma, Burkitt-like (130)
- Diffuse large B-cell lymphoma (107)
- Mediastinal large B-cell lymphoma (125)
- Primary effusion lymphoma (138)
- Extranodal marginal zone B-cell lymphoma of MALT type (122)
- Follicular lymphoma (includes variants) (121)
- Lymphoplasmacytic lymphoma (121)
- Mantle cell lymphoma (115)
- Nodal marginal zone B-cell lymphoma (116)
- ( +/- monocyteid B cells) (123)
- Primary CNS lymphoma (118)
- Splenic marginal zone B-cell lymphoma (124)
- Waldenstrom macroglobulinemia (173)
- Other B-cell lymphoma (129), specify: ______________________

#### T-cell and NK-cell Neoplasms 244. (continued)

- Adult T-cell lymphoma/leukemia (HTLV1+) (134)
- Aggressive NK-cell leukemia (27)
- Anaplastic large-cell lymphoma, T/null cell, primary cutaneous type (147)
- Anaplastic large-cell lymphoma, T/null cell, primary systemic type (148)
- Angioimmunoblastic T-cell lymphoma (AILD) (131)
- Enteropathy-type T-cell lymphoma (133)
- Extranodal NK/T-cell lymphoma, nasal type (137)
- Hepatosplenic gamma-delta T-cell lymphoma (145)
- Mycosis fungoides (141)
- Peripheral T-cell lymphoma (130)
- Subcutaneous panniculitis-like T-cell lymphoma (146)
- Sezary syndrome (142)
- Large T-cell granular lymphocytic leukemia (126)
- Other T/NK cell lymphoma (139), specify: ______________________

### Sensitivity to Chemotherapy

- Sensitivity (HL 243.)
- Resistant
- Untreated
- Unknown

### Status at Transplantation

- Never treated
- Primary refractory (less than PR to initial therapy)/PIF res
- Partial response (PR)
- Without prior CR
- With prior CR
- CR confirmed
- CR unconfirmed (CRU)*
- Rel

### Number

- 1st
- 2nd
- 3rd or higher

* CRU – complete response with persistent scan abnormalities of unknown significance
### Pre-Transplant Essential Data

**Classifications**

#### PLASMA CELL DISORDERS (170)

- Multiple myeloma-lgG (181)
- Multiple myeloma-lgA (182)
- Multiple myeloma-lgD (183)
- Multiple myeloma-lgE (184)
- Multiple myeloma-lgM (not Waldenstrom macroglobulinemia) (185)
- Multiple myeloma-light chain only (186)
- Multiple myeloma-non-secretory (187)
- Plasma cell leukemia (172)
- Solitary plasmacytoma (no evidence of myeloma) (175)
- Primary Amyloidosis (174)
- Other Plasma Cell Disorder (179), specify: _______________________

#### Status at Transplantation:

- Never treated
- Complete Remission (CR)
- Stringent Complete Remission (sCR)
- Very Good Partial Response (VGPR)
- Partial Response (PR)
- Stable Disease (SD)
- Progression
- Relapse from CR (untreated)

#### StAGE AT DIAGNOSIS

- **Light Chain**
  - Kappa
  - Lambda
- **Salmon & Durie**: 1 and A
- **I.S.S.**:
  - Serum $\beta_2$-microglobulin: 1 $\mu$g/dL 2 mg/L 3 nmol/L
- **Serum albumin**: 1 g/dl 2 g/l

#### BREAST CANCER (250)

- Breast Cancer
  - Inflammatory (251)
  - Non-inflammatory (252)

#### Status at Transplantation:

- Adjuvant (Stage II, III only)
- Never treated
- Primary refractory
- Complete remission (CR)
- CR confirmed
- CR unconfirmed (CRU)
- 1st partial response (PR1)
- Relapse
- Local
- Metastatic

#### Sensitivity to Chemotherapy

- Sensitive
- Resistant
- Untreated
- Unknown

### Other" DISEASE (900)

Specify (900): 272.

Before using this category, check with transplant physician whether diagnosis can be classified among options on Disease Classification Pages 3-10.

For any "other" disease: Is a pathology report attached to this form?

- Yes
- No

---

### Pre-Transplant Essential Data

#### Disease Classification Sheet

**Classification:**
- Bone sarcoma (excluding Ewing family tumors) (273)
- Central nervous system tumors (include CNS PNET) (220)
- Colorectal (228)
- Ewing family tumors extra-osseous (includes PNET) (276)
- Ewing family tumors of bone (includes PNET) (275)
- Germ cell tumor, extragonadal only (225)
- Hepatobiliary (207)
- Lung cancer, non-small cell (203)
- Lung cancer, small cell (202)
- Medulloblastoma (226)
- Melanoma (219)
- Neuroblastoma (222)
- Ovary (214)

**Status at Transplantation:**
- Adjuvant
- Never treated
- CR
- CRU
- PR
- NR/SD
- PD
- Relapse (untreated)

**Response Evaluation Criteria in Solid Tumors (RECIST) was used for this status evaluation:**
- Yes
- No

1. **Complete response (CR)** – Disappearance of all target lesions for a period of at least one month
2. **Partial response (PR)** – At least 30% decrease in the sum of the longest diameter of measured lesions (target lesions) taking as reference the baseline sum of longest diameters
3. **Stable disease (NR/SD)** – Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of the longest diameters since the treatment started
4. **Progressive disease (PD)** – At least a 20% increase in the sum of the longest diameter of measured lesions (target lesions), taking as reference the smallest sum of the longest diameters recorded since the treatment started

**Number:**
- (complete for CR, CRU or relapse)
- 1st
- 2nd
- 3rd or higher

**Sensitivity to Chemotherapy:**
- Yes
- No

1. **Sensitive (PR)**
2. **Resistant (SD, PD)**
3. **Untreated**
4. **Unknown**

---

**Severe aplastic anemia**

**Classification:**
- Acquired Severe Aplastic Anemia (SAA), NOS (301)
- Acquired SAA, secondary to hepatitis (302)
- Acquired SAA, secondary to toxin/other drug (303)
- Acquired Amegakaryocytosis (not congenital) (304)
- Acquired Pure Red Cell Aplasia (PRCA) (not congenital) (305)
- Other acquired cytopenic syndrome (306)

**Specify:**
- Paroxysmal nocturnal hemoglobinuria (PNH) (56)

**Inherited abnormalities of erythrocyte differentiation or function:**
- Fanconi anemia (307)
- Diamond-Blackfan anemia (congenital PRCA) (308)
- Other constitutional anemia (309)

**Specify:**
- Sickle cell disease (310)
- Sickle thalassemia (311)
- Thalassemia (312)
- Other hematologic anomaly (313)

---

**Hematopoietic Stem Cell Transplantation (HSCT)**

**Remaining Toxicities:**
- 1st year post-HSCT
- 2nd year post-HSCT
- 3rd or higher year post-HSCT

**Sensitivity to Chemotherapy:**
- Yes
- No

1. **Sensitive (PR)**
2. **Resistant (SD, PD)**
3. **Untreated**
4. **Unknown**

---

**Platelet Disorders (500)**

**Classification:**
- Congenital amegakaryocytosis/congenital thrombocytopenia (501)
- Glanzmann thrombasthenia (502)
- Other inherited platelet abnormalities (503)

**Specify:**
- Other inherited platelet abnormalities (503)

---

**Histiocytic Disorders (570)**

**Classification:**
- Histiocytic disorders, NOS (570)
- Familial erythro/hemophagocytic lymphohistiocytosis (FELH) (571)
- Langerhans Cell Histiocytosis (Histiocytosis-X) (572)
- Hemophagocytosis (reactive or viral associated) (573)
- Malignant histiocytosis (574)
- Other histiocytic disorder (575)

---

**CR** = complete remission
### Pre-Transplant Essential Data

#### Disease Classification Sheet

**177** INHERITED DISORDERS OF METABOLISM/OSTEOPETROSIS (520)

- Adrenoleukodystrophy (ALD) (543)
- Aspartyl glucosaminuria (561)
- B-glucuronidase deficiency (VII) (537)
- Fucosidosis (562)
- Gaucher disease (541)
- Glucose storage disease (548)
- Hunter syndrome (II) (533)
- Hurler syndrome (IH) (531)
- I-cell disease (546)
- Krabbe disease (globoid leukodystrophy) (544)
- Lesch-Nyhan (HGPRT deficiency) (522)
- Mannosidosis (563)
- Maroteaux-Lamy (VI) (536)
- Metachromatic leukodystrophy (MLD) (542)
- Morquio (V) (535)
- Mucolipidoses, NOS (540)
- Mucopolysaccharidosis (V) (538)
- Mucopolysaccharidosis, NOS (530)
- Neimann-Pick disease (545)
- Neuronal ceroid – lipofuscinoses (Batten disease) (523)
- Osteopetrosis (malignant infantile osteopetrosis) (521)
- Sanfilippo (III) (534)
- Scheie syndrome (IS) (532)
- Wolman disease (547)
- Other inherited disorder of metabolism (629), specify:____________________
- Inherited Disorders of Metabolism, NOS (520)

**294** IMMUNE DEFICIENCIES (400)

- Ataxia telangiectasia (451)
- Bare lymphocyte syndrome (406)
- DiGeorge anomaly (454)
- CD 40 Ligand deficiency (464)
- Cartilage hair hypoplasia (462)
- Chediak-Higashi syndrome (456)
- Chronic granulomatous disease (455)
- Common variable immunodeficiency (457)
- HIV infection (452)
- Immune Deficiencies, NOS (400)
- Leukocyte adhesion deficiencies (459)
- Kostmann syndrome-congenital neutropenia (460)
- Neutrophil actin deficiency (461)
- Omenn syndrome (404)
- Reticular dysgenesis (405)
- SCID, ADA deficiency severe combined immune deficiency (401)
- SCID, Absence of T and B cells (402)
- SCID, Absence of T, normal B cell (403)
- SCID, NOS (410)
- SCID other (419), Specify: 295.
- Wiskott Aldrich syndrome (403)
- X-linked lymphoproliferative syndrome (458)
- Other immune deficiency (479), specify: 296.
### Pre-Transplant Essential Data

#### Disease Classification Sheet

**AUTOIMMUNE DISORDERS (600)**

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Connective Tissue Disease</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>297. Systemic sclerosis (607)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>298. diffuse cutaneous</td>
<td>Yes</td>
<td>Antibodies:</td>
<td></td>
</tr>
<tr>
<td>300. limited cutaneous</td>
<td>Yes</td>
<td>normal</td>
<td></td>
</tr>
<tr>
<td>302. lung parenchyma</td>
<td>Yes</td>
<td>elevated</td>
<td></td>
</tr>
<tr>
<td>304. pulmonary hypertension</td>
<td>Yes</td>
<td>not done</td>
<td></td>
</tr>
<tr>
<td>306. systemic hypertension</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>308. renal (biopsy type: 310.)</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>311. esophagus</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>313. other GI Tract</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>315. Raynaud</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>317. CREST</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>319. other, specify 321.</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Systemic lupus erythematosus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>297. SLE (606)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>299. renal (biopsy type: 327. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>301. CNS (type: 339. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>303. PNS (type: 333. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>305. lung</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>307. serositis</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>309. arthritis</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>310. skin (type: 342. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>312. hematological (type: 345. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>314. vasculitis (type: 348. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>316. other, specify 351.</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sjögren syndrome</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>297. (608)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>318. SICCA</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>320. exocrine gland swelling</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>322. other organ lymphocytic infiltration</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>324. lymphoma, paraproteinemia</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>326. vasculitis</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>328. other, specify 371.</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Polymyositis-dermatomyositis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>297. (608)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>329. proximal weakness</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>331. generalized weakness (including bulbar)</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>333. pulmonary fibrosis</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>335. vasculitis (type: 390. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>337. malignancy (type: 383. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>339. other, specify 386.</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antiphospholipid syndrome</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>297. (613)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>330. thrombosis (type: 383. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>332. CNS (type: 396. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>334. infection</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>336. abortion</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>338. skin (livedo, vasculitis)</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>340. hematological (type: 403. )</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>342. other, specify 406.</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other connective tissue disease, specify 634:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Vasculitis** | | | |
| 297. Wegener granulomatosis (610) | | | |
| 411. upper respiratory tract | Yes | Antibodies: | |
| 413. pulmonary | Yes | c-ANCA positive | |
| 415. renal (biopsy type: 417. ) | Yes | anti Pr3 | |
| 418. skin | Yes | anti MPO | |
| 420. other, specify: 422. | Yes | c-ANCA IFA | |

| 297. Polyarteritis nodosa | | | |
| Classical (631) | | | |
| Microscopic (632) | | | |
| 423. renal (type: 430. ) | Yes | p-ANCA positive | |
| 431. mononeuritis multiplex | Yes | c-ANCA positive | |
| 433. pulmonary hemorrhage | Yes | c-ANCA positive | |
| 435. skin | Yes | hepatitis serology | |

**NOTE:** Transplant Essential Data should be submitted at time of mobilization for all patients with autoimmune disease.
### Disease Classification Sheet

**177. AUTOIMMUNE DISORDERS**

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Other vasculitis</strong></td>
<td>(Check all that apply)</td>
<td>(Check all that apply)</td>
<td></td>
</tr>
<tr>
<td>- Churg-Strauss (635)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Giant cell arteritis (636)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Takayasu (637)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Behçet's Syndrome (638)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- overlap necrotizing arteritis (639)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- other vasculitis, specify (611):______________________</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Arthritis**

- Rheumatoid arthritis (603)
  - 446. destructive arthritis
  - 448. necrotizing vasculitis
  - 450. eye (type: ____________)
  - 453. pulmonar
  - 455. extra-articular (specify: ____________)
  - 458. other, specify: ____________

- Psoriatic arthritis/psoriasis (604)
  - 461. destructive arthritis
  - 463. psoriasis
  - 465. other, specify: ____________

**Juvenile idiopathic arthritis**

- Systemic (Stills disease) (640)
- Oligoarticular (641)
- Polyarticular (642)
- Other, specify (643): ____________

**Multiple sclerosis**

- 470. primary progressive
- 472. secondary progressive
- 474. relapsing/remitting
- 476. other specify: ____________

**Other Neurological Autoimmune Disease**

- 479. Myasthenia gravis (601)
- Other autoimmune neurological disorder, specify (644): ____________

**Hematological Autoimmune Disease**

- 480. Idiopathic thrombocytopenic purpura (ITP) (645)
- 481. Hemolytic anemia (646)
- 482. Evan syndrome (647)
- Other autoimmune cytopenia, specify (648): ____________

**Bowel Disease**

- 483. Crohn's disease (640)
- 484. Ulcerative colitis (650)
- Other autoimmune bowel disorder, specify (651): ____________